Evidence map›Paper›PMID 24349182›Full record

ArticlePloS one2013

Geotemporal analysis of Neisseria meningitidis clones in the United States: 2000-2005.

Ann E Wiringa, Kathleen A Shutt, Jane W Marsh, Amanda C Cohn, Nancy E Messonnier, Shelley M Zansky, Susan Petit, Monica M Farley, Ken Gershman, Ruth Lynfield and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

Ann E WiringaDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, United States of America.
Kathleen A ShuttInfectious Diseases Epidemiology Research Unit, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Jane W MarshInfectious Diseases Epidemiology Research Unit, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Amanda C CohnMeningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Nancy E MessonnierMeningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Shelley M ZanskyNew York State Department of Health, Albany, New York, United States of America.
Susan PetitConnecticut Department of Public Health, Hartford, Connecticut, United States of America.
Monica M FarleyEmory University and VA Medical Center, Atlanta, Georgia, United States of America.
Ken GershmanColorado Department of Public Health and Environment, Denver, Colorado, United States of America.
Ruth LynfieldMinnesota Department of Health, St. Paul, Minnesota, United States of America.
Arthur ReingoldUniversity of California, Berkeley, Berkeley, California, United States of America.
William SchaffnerVanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Jamie ThompsonOregon Public Health Division, Portland, Oregon, United States of America.
Shawn T BrownPittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.
Bruce Y LeePublic Health Computational and Operations Research (PHICOR), University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, Pennsylvania, United States of America.
Lee H HarrisonInfectious Diseases Epidemiology Research Unit, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania, United States of America ; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
University of Pittsburgh · USCenters for Disease Control and Prevention · USAtlanta VA Medical Center · USColorado Department of Public Health and Environment · USConnecticut Department of Public Health · USMinnesota Department of Health · USNew York State Department of Health · USOregon Health Authority · USPittsburgh Supercomputing Center · USUniversity of California, Berkeley · USVanderbilt University · US

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThe detection of meningococcal outbreaks relies on serogrouping and epidemiologic definitions. Advances in molecular epidemiology have improved the ability to distinguish unique Neisseria meningitidis strains, enabling the classification of isolates into clones. Around 98% of meningococcal cases in the United States are believed to be sporadic.

methodsMeningococcal isolates from 9 Active Bacterial Core surveillance sites throughout the United States from 2000 through 2005 were classified according to serogroup, multilocus sequence typing, and outer membrane protein (porA, porB, and fetA) genotyping. Clones were defined as isolates that were indistinguishable according to this characterization. Case data were aggregated to the census tract level and all non-singleton clones were assessed for non-random spatial and temporal clustering using retrospective space-time analyses with a discrete Poisson probability model.

resultsAmong 1,062 geocoded cases with available isolates, 438 unique clones were identified, 78 of which had ≥2 isolates. 702 cases were attributable to non-singleton clones, accounting for 66.0% of all geocoded cases. 32 statistically significant clusters comprised of 107 cases (10.1% of all geocoded cases) were identified. Clusters had the following attributes: included 2 to 11 cases; 1 day to 33 months duration; radius of 0 to 61.7 km; and attack rate of 0.7 to 57.8 cases per 100,000 population. Serogroups represented among the clusters were: B (n = 12 clusters, 45 cases), C (n = 11 clusters, 27 cases), and Y (n = 9 clusters, 35 cases); 20 clusters (62.5%) were caused by serogroups represented in meningococcal vaccines that are commercially available in the United States.

conclusionsAround 10% of meningococcal disease cases in the U.S. could be assigned to a geotemporal cluster. Molecular characterization of isolates, combined with geotemporal analysis, is a useful tool for understanding the spread of virulent meningococcal clones and patterns of transmission in populations.

Indexed as

Spatio-Temporal AnalysisBacterial Outer Membrane ProteinsClone CellsEpidemiological MonitoringGene ExpressionHumansMeningococcal InfectionsMultilocus Sequence TypingNeisseria meningitidisRetrospective StudiesSerotypingUnited StatesBacterial Outer Membrane Proteins

Identifiers

PMID24349182
PMCPMC3861328
OpenAlexW2132640431

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.